Factor XIII Deficiency
A rare inherited disorder affecting the enzyme that stabilizes blood clots, caused by mutations in the F13A1 or F13B genes, leading to delayed bleeding and impaired wound healing.
- Autosomal Recessive Inheritance
- Delayed Bleeding Pattern
- Specialist Hematology Care
- Estimated Prevalence
- ~1 in 2,000,000-5,000,000
- Inheritance Pattern
- Autosomal Recessive
- Genes Involved
- F13A1, F13B
- Care Access
- Specialist Hematology & Prophylactic Therapy
Condition Overview
Factor XIII deficiency is one of the rarest inherited bleeding disorders, caused by mutations in the F13A1 or F13B genes. Unlike most coagulation factors that act early in clot formation, Factor XIII acts at the final step, cross-linking fibrin strands to stabilize and strengthen the clot once it has formed.
Because of this unique role, deficiency often presents differently from other bleeding disorders: initial clot formation and screening coagulation tests can appear normal, but clots that do form are fragile and break down prematurely, leading to delayed bleeding hours to days after injury or surgery.
Severe congenital Factor XIII deficiency is associated with one of the highest risks of umbilical cord bleeding and intracranial hemorrhage among inherited bleeding disorders, making early recognition and lifelong prophylaxis particularly important in confirmed severe cases.
Types and Variants
Factor XIII deficiency is classified by the affected subunit and by congenital versus acquired origin.
Symptoms and Signs
A hallmark feature of Factor XIII deficiency is delayed-onset bleeding, often appearing after initial hemostasis seems adequate.
Causes and Risk Factors
Factor XIII deficiency most commonly results from inherited mutations affecting the enzyme's structure or function, with rare acquired forms also recognized.
Diagnosis and Investigations
Because standard clotting screens are typically normal, diagnosis of Factor XIII deficiency requires specific testing aimed at clot stability.
Severity Classification
Factor XIII deficiency is classified by residual factor activity and clinical bleeding history rather than staged like cancer.
Standard Treatment Options
Because severe Factor XIII deficiency carries a high bleeding risk, including intracranial hemorrhage, regular prophylaxis rather than only on-demand treatment is central to management.
Advanced and Emerging Therapies
Recombinant Factor XIII products and ongoing research are improving long-term management options for this rare disorder.
Recombinant Factor Replacement
Recombinant Factor XIII-A2 Concentrate
Approved for prophylaxis in congenital Factor XIII A-subunit deficiency, reducing reliance on plasma-derived products.
Plasma-Derived Factor Replacement
Plasma-Derived Factor XIII Concentrate
Used for prophylaxis and treatment in both subunit deficiency types where recombinant product is not applicable.
Specialist Hematology Access
Cross-Border Specialist Coordination
Access to comprehensive bleeding disorder centers experienced in managing this very rare condition.
Biomarkers and Laboratory Monitoring
Targeted laboratory tests, distinct from standard clotting panels, are essential for diagnosing and monitoring Factor XIII deficiency.
When a Second Opinion May Be Important
Given how rare and easily missed Factor XIII deficiency can be, specialist review is valuable at several points in care.
Clinical Trials and Research
Prognosis and Outlook
With consistent prophylactic therapy and specialist follow-up, the historically high risk of life-threatening bleeding in severe Factor XIII deficiency can be substantially reduced.
Supportive Care and Living With Factor XIII Deficiency
Because of the elevated bleeding risk in severe disease, structured supportive care plays a central role in day-to-day management.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Factor XIII deficiency access specialist hematology review, coordinate second opinions on prophylaxis planning, and connect with comprehensive bleeding disorder treatment centers internationally.
Get a free case reviewFrequently Asked Questions
Factor XIII deficiency is an extremely rare inherited bleeding disorder caused by mutations in the F13A1 or F13B genes, affecting the enzyme that stabilizes blood clots after they form.
Because Factor XIII acts after the clot has already formed to stabilize it, the standard PT and aPTT tests, which measure clot formation timing, are typically unaffected.
Delayed bleeding from the umbilical stump is one of the most characteristic early signs of severe congenital Factor XIII deficiency.
It follows an autosomal recessive pattern, requiring mutations in both copies of the F13A1 or F13B gene for severe disease.
Severe Factor XIII deficiency carries one of the highest risks of spontaneous intracranial bleeding among inherited bleeding disorders, making prophylaxis especially important.
Regular prophylactic infusions of recombinant or plasma-derived Factor XIII concentrate are the mainstay of treatment for severe disease.
Yes, affected women have an increased risk of recurrent pregnancy loss, and testing should be considered in unexplained cases.
There is no permanent cure, but regular prophylactic therapy substantially reduces the risk of serious bleeding complications.
Genetic counseling and testing of close relatives can identify carriers or affected individuals, particularly in families with a known mutation.
Yes. CancerFax helps patients with Factor XIII deficiency get their medical reports reviewed by specialists, coordinate second opinions, and connect with comprehensive bleeding disorder centers and advanced therapy access internationally.
Get Expert Guidance for Factor XIII Deficiency
Send your medical reports for specialist hematology review and explore coordinated prophylaxis planning.